90. Breast. 2018 Jul 12;41:137-143. doi: 10.1016/j.breast.2018.07.004. [Epub ahead ofprint]T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breastcancer.Fabi A(1), Alesini D(2), Valle E(3), Moscetti L(4), Caputo R(5), Caruso M(6),Carbognin L(7), Ciccarese M(8), La Verde N(9), Arpino G(10), Cannita K(11), ParisI(12), Santini D(13), Montemurro F(14), Russillo M(2), Ferretti G(2), Filippelli G(15), Rossello R(16), Fabbri A(17), Zambelli A(18), Leonardi V(19), D'OttavioAM(20), Nisticò C(2), Stani S(21), Giampaglia M(22), Scandurra G(23), CataniaG(2), Malaguti P(2), Giannarelli D(24), Cognetti F(2).Author information: (1)Oncologia Medica 1, Istituto Nazionale Tumori "Regina Elena", Roma, Italy.Electronic address: alessandra.fabi@virgilio.it.(2)Oncologia Medica 1, Istituto Nazionale Tumori "Regina Elena", Roma, Italy.(3)Oncologia Medica, Ospedale Businco, Cagliari, Italy.(4)Oncologia Medica, Ospedale Modena, Modena, Italy.(5)Breast Unit, Istituto Pascale, Napoli, Italy.(6)Humanitas Centro Catanese di Oncologia, Catania, Italy.(7)Oncologia Medica, Università di Verona, Italy.(8)Oncologia, Ospedale Vito Fazi, Lecce, Italy.(9)Oncologia Medica, PO Fatebenefratelli e Oftalmico, Milano, Italy.(10)Oncologia Medica, Università Federico II, Napoli, Italy.(11)Oncologia Medica, Ospedale S. Salvatore, Università dell'Aquila, Italy.(12)Oncologia e Ginecologica Polo Donna, Policlinico A.Gemelli, Roma, Italy.(13)Oncologia Medica, Campus Bio-medico Universitario, Roma, Italy.(14)Investigative Clinical Oncology, Cancer Institute-FPO, IRCCS, Candiolo,Torino, Italy.(15)Oncologia P.O. di Paola, Cosenza, Italy.(16)Oncologia Medica, Ospedale S. Vincenzo, Taormina, Messina, Italy.(17)Oncologia Medica, Ospedale Belcolle, Viterbo, Italy.(18)Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy.(19)Oncologia Medica, ARNAS Civico, Palermo, Italy.(20)Oncologia Medica, Ospedale San Giovanni, Roma, Italy.(21)Oncologia Medica, Ospedale Santo Spirito, Roma, Italy.(22)Oncologia Medica, Ospedale San Carlo, Potenza, Italy.(23)Oncologia Medica, Ospedale per le Emergenze Cannizzaro, Catania, Italy.(24)Unità di Biostatistica, Istituto Nazionale Tumori "Regina Elena", Roma,Italy.BACKGROUND: We reported the results of an Italian large retrospective analysisthat evaluated the effectiveness and safety of T-DM1 in 'field-practice' breastcancer patients. We performed a sub-analysis to investigate the clinical activityof T-DM1 in patients with brain metastases (BMs).METHODS: The records of 87 adult women with HER2-positive breast cancer and BMstreated with T-DM1 were reviewed. Their clinical outcomes were compared withthose of 216 patients without central nervous system (CNS) involvement.RESULTS: Response to T-DM1 treatment in BMs was available for 53 patients in the BM group (60.9%): two patients reported a complete response (3.8%), 11 patientsobtained partial response (20.7%; overall response rate: 24.5%), 16 patients had a stable disease (30.1%). Regarding extracranial disease, a total of 77 and 191patients were evaluable for response in BM group and non-BM group, respectively. The overall response rate was 35.1% in the BM group and 38.3% in the non-BMgroup; disease control rate was 53.3% and 66.6%, respectively. At a medianfollow-up of 16 months (range: 1-55), median cumulative progression-free survival(PFS) was 7 months (95% CI: 5.4-8.6) in the BM group and 8 months (95% CI:5.7-10.3) in the non-BM group. In the second-line setting, PFS was 5 (95% CI:3.1-6.9) versus 11 (95% CI: 7.1-14.9) months (p = 0.01). Overall survival was 14 months (95% CI: 12.2-15.8) in the BM group and 32 months (95% CI: 24.4-39.6) inthe non-BM group (p < 0.0001).CONCLUSIONS: T-DM1 is active in breast cancer patients with BMs.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.breast.2018.07.004 PMID: 30092500 